Background: Social media platforms have emerged as a valuable data source for public health research and surveillance. Monitoring of social media and user-generated data on the Web enables timely and inexpensive collection of information, overcoming time lag and cost of traditional health reporting systems.
Objectives: This article identifies personally experienced coronavirus disease 2019 (COVID-19) vaccine reactions expressed on Twitter and validate the findings against an established vaccine reactions reporting system.
Methods: We collected around 3 million tweets from 1.4 million users between February 1, 2021, to January 31, 2022, using COVID-19 vaccines and vaccine reactions keyword lists. We performed topic modeling on a sample of the data and applied a modified F1 scoring technique to identify a topic that best differentiated vaccine-related personal health mentions. We then manually annotated 4,000 of the records from this topic, which were used to train a transformer-based classifier to identify likely personally experienced vaccine reactions. Applying the trained classifier to the entire data set allowed us to select records we could use to quantify potential vaccine side effects. Adverse events following immunization (AEFI) referred to in these records were compared with those reported to the state of Victoria's spontaneous vaccine safety surveillance system, SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community).
Results: The most frequently mentioned potential vaccine reactions generally aligned with SAEFVIC data. Notable exceptions were increased Twitter reporting of bleeding-related AEFI and allergic reactions, and more frequent SAEFVIC reporting of cardiac AEFI.
Conclusion: Social media conversations are a potentially valuable supplementary data source for detecting vaccine adverse event mentions. Monitoring of online observations about new vaccine-related personal health experiences has the capacity to provide early warnings about emerging vaccine safety issues.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812583 | PMC |
http://dx.doi.org/10.1055/a-1975-4061 | DOI Listing |
Zhonghua Yu Fang Yi Xue Za Zhi
January 2025
Immunization Program Institute of Shaanxi Provincial Center for Disease Control and Prevention, Xi'an 710054, China.
To investigate the safety of the tetravalent meningococcal conjugate vaccine (MPCV-ACYW) in combination with the inactivated poliomyelitis (IPV) vaccine and diphtheria-tetanus-acellular pertussis (DTaP) vaccine for infants aged 3-5 months and provide real-world evidence for the immunization strategy of vaccine combination. From June to October 2023, a total of 600 3-month-old infants were selected and divided into three groups: control group, mono-vaccination group and combined vaccination group. They were simultaneously or individually vaccinated with MPCV-ACYW, IPV and DTaP vaccines at 3, 4, and 5 months of age, respectively.
View Article and Find Full Text PDFReumatismo
January 2025
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome; Unicamillus, Saint Camillus International University of Health Sciences, Rome.
Objective: To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients.
Methods: Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination.
Front Allergy
January 2025
Allergy and Immunology Division, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
Introduction: COVID-19 vaccination has been a key intervention in reducing the severity of symptoms; however, concerns about vaccine safety, particularly regarding allergic reactions, arose early on. Healthcare workers faced the challenge of addressing these concerns to ensure safe vaccine administration. This study aimed to review the practical aspects of using allergy skin testing for COVID-19 vaccine excipients in patients with a history of allergic reactions developed following mRNA COVID-19 vaccination.
View Article and Find Full Text PDFJ Allergy Clin Immunol Glob
February 2025
Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China.
Background: Adverse effects following immunizations (AEFIs) can contribute to vaccine hesitancy.
Objective: We evaluated clinical outcomes of AEFIs subsequent to administration of the coronavirus disease 2019 (COVID-19) vaccine at 2 pediatric allergy centers.
Methods: Data on pediatric patients referred for COVID-19 AEFI concerns between March 2021 and October 2022 were reviewed.
J Allergy Clin Immunol Glob
February 2025
the Department of Pediatrics, New York University Grossman School of Medicine, New York, NY.
Background: Management of patients with food allergies is complex, especially in cases of patients with multiple and potentially severe food allergies. Although international guidelines exist for food allergy management, the role of the allergist in the decision-making process is key.
Objective: Our aim was to investigate the management patterns and educational needs of practicing allergists treating patients with food allergies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!